Clinicians Need New Standards for Interpreting AI-Wearable Physiologic Data

As wearable devices become ubiquitous health monitors, the flood of continuous physiologic data they generate is quietly reshaping clinical medicine — often without the interpretive tools needed to act on it responsibly. The gap between what these devices measure and what clinicians can meaningfully do with those measurements is widening, and a perspective in JAMA now attempts to address that structural problem head-on.

The framework introduces the concept of "results of unknown significance" (RUS) — a formal category for wearable-derived physiologic signals that fall outside established diagnostic norms but lack sufficient evidence to guide clinical decisions. Distinct from incidental findings on imaging or genomic variants of uncertain significance (VUS), RUS encompasses continuous streams of data such as heart rate variability, sleep stage architecture, skin temperature fluctuations, and SpO2 patterns. The authors argue that without universal evidentiary standards and shared clinical language, these signals risk being simultaneously over-acted upon and under-appreciated, depending on the clinician's familiarity with the technology.

This framing matters because the wearable market has outpaced regulatory and clinical evidence infrastructure. Devices cleared under FDA's 510(k) pathway for general wellness often carry no randomized trial evidence linking their alerts to meaningful outcomes. The parallel to genomic medicine is instructive: the field spent years developing classification systems for variants of uncertain significance precisely because ambiguity without structure leads to inconsistent care. Applying analogous rigor to physiologic wearable data is arguably overdue. The perspective's call for shared language is incremental rather than paradigm-shifting, but it addresses a genuine clinical bottleneck. Key limitations include the absence of outcome data linking RUS management strategies to patient benefit, and the framework remains theoretical — validation across diverse clinical settings will be essential before adoption at scale.